Bone scan index: A Quantitative treatment response biomarker for castration-resistant metastatic prostate cancer

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 519-524

  Dennis, Elizabeth R ^a   Jia, Xiaoyu ^a   Mezheritskiy, Irina S ^a   Stephenson, Ryan D ^a   Schoder, Heiko ^a   Fox, Josef J ^a   Heller, Glenn ^a   Scher, Howard I ^a,b   Larson, Steven M ^a   Morris, Michael J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCAN INDEX; BONE SCINTISCANNING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MUSCULOSKELETAL SYSTEM PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MODELS, THEORETICAL; ODDS RATIO; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856927346     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.5791     Document Type: Article

References (12)

1. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
2. Soloway MS, Hardeman SW, Hickey D, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195-202, 1988 (Pubitemid 18023133)
3. Amico S, Liehn JC, Desoize B, et al: Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin Nucl Med 16:643-648, 1991
4. Chybowski FM, Keller JJ, Bergstralh EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145:313-318, 1991
5. Imbriaco M, Larson SM, Yeung HW, et al: A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index. Clin Cancer Res 4:1765-1772, 1998 (Pubitemid 28304740)
6. Ellis RE: The distribution of active bone marrow in the adult. Phys Med Biol 5:255-258, 1961
7. International Commission on Radiological Protection: Report on the Task Group on Reference Man. New York, NY, Pergamon Press, ICRP Publication 23, 1975
8. Larson SM, Nelp WB: The radiocolloid bone marrow scan in malignant disease. J Surg Oncol 3:685-697, 1971
9. Sabbatini P, Larson SM, Kremer A, et al: Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948-957, 1999 (Pubitemid 29109328)
10. Gentleman R, Crowley J: Graphical methods for censored data. J Am Stat Assoc 86:678-683, 1991
11. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003 (Pubitemid 46606398)
12. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982, 2002